Results of an Australian trial of an automated insulin delivery (AID) system and other studies support likely benefit of AID use for many Australian adults with type 1 diabetes
journal contribution
posted on 2025-05-06, 06:30 authored by AJ Jenkins, AS Januszewski, A Kirby, Christel Hendrieckx, SA McAuley, MH Lee, B Paldus, S Vogrin, MI de Bock, MB Abraham, LA Bach, MG Burt, ND Cohen, PG Colman, EA Davis, DJ Holmes-Walker, J Kaye, AC Keech, K Kumareswaran, RJ MacIsaac, RW McCallum, CM Sims, Jane SpeightJane Speight, SN Stranks, V Sundararajan, S Trawley, GM Ward, TW Jones, DN O'Neal, Jennifer HallidayJennifer Halliday, S Russell-Green, HM Husin, PM Clarke, GR Ambler, FJ Cameron, JM Fairchild, BR KingAbstractLess than 20% of Australians with type 1 diabetes (T1D) meet recommended glucose targets. Technology use is associated with better glycaemia, with the most advanced being automated insulin delivery (AID) systems, which are now recommended as gold‐standard T1D care. Our Australian AID trial shows a wide spectrum of adults with T1D can achieve recommended targets. Other studies, including lived experience data, are supportive. Insulin pumps are not subsidised for most Australian adults with T1D. We advocate change.
History
Related Materials
- 1.
Location
London, Eng.Open access
- No
